Oxford Biomedica

Overview

Oxford Biomedica (OXB) is a global, quality and innovation-led viral vector CDMO specializing in contract development and manufacturing of cell and gene therapy products. Founded in 1995 as a spin-out from the University of Oxford, OXB has evolved into a trusted partner for leading biopharma companies, offering comprehensive CDMO solutions across the viral vector lifecycle.

Core Capabilities

Viral Vector Platforms:

• Lentivirus: 30 years of pioneering experience in lentiviral vector development and manufacturing, supporting clients from early development through commercialization. Scalable production from 50L to 1000L across harmonized global facilities.
• AAV: Proprietary inAAVate™ platform delivers GMP-grade AAV in as little as 7 months. Achieves industry-leading titres (1.5E+17 vgs from 500L bioreactor) with 90% full capsids, maximizing doses per batch.
• Adenovirus: Proven large-scale manufacturing expertise, including production of over 100 million doses of Oxford–AstraZeneca COVID-19 vaccine. Advanced GMP infrastructure across multiple geographies.
• Other Vectors: Capabilities in MVA (Modified Vaccinia Ankara) and other poxvirus-based vectors for immuno-oncology and infectious disease vaccines.

Service Models:

• Platform projects for preclinical/early-clinical clients seeking accelerated GMP timelines via proven processes
• Custom solutions offering flexibility for early-stage development
• Technology transfer services for Phase I–III programs requiring scale-up and long-term manufacturing

Regulatory & Quality:

• End-to-end regulatory support from preclinical development through commercial launch
• Successfully supported multiple IND and MAA submissions
• Maintains FDA Drug Master File (DMF)
• GMP-compliant facilities across UK, Europe, and USA

Global Infrastructure

State-of-the-art facilities in the UK, US, and France provide multi-vector capabilities aligned to global regulatory standards, enabling scalable, resilient manufacturing with geographic flexibility.